07.09.24 -- A GSK Guide To Outsourcing Early-Stage Development

Not really into choosing extended time away and exhibit halls over the simple pleasures of summertime? No reason to put your CDMO search on hold – Outsourced Pharma Capacity Update’s PARTNER WEEK is here! Take the travel and headache out of your plans and join us right from your computer. Assess potential fit for your next drug development project in convenient 20-minute segments – all grouped by molecule type. Presenters will share current available capacity across featured capabilities. Register for free.

Drug developers might want to consider longer-term approaches to meeting manufacturing and regulatory requirements.

Discover why Cas9 mRNA is the preferred choice for precise gene editing, offering efficient delivery, transient expression, and flexible targeting.

Achieve your therapeutic and commercial goals by utilizing a tried-and-tested standardized approach combined with the latest technology and reliable analytics.

Review how the upstream and downstream workflows of a lentiviral vector platform were optimized through the use of design of experiments and supplementary studies.

Explore considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, and collaborations.

Examine how the world’s largest and most diverse collection of novel RGNs and deaminases is increasing the potential for addressing the needs of CF patients with nonsense mutations.

Watch to gain valuable insights into the characterization of cellular source material for the development and manufacture of cell and gene therapy-based products.

Our AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.

Explore our end-to-end, customer-centric CDMO services that are helping to bring more breakthrough treatments to patients.

Learn how our proven methodology and decades-long AAV database at the core of the AAV Curator Platform directly drives speed, maximizes yields, and delivers a high-quality product.

Translating mRNA sequence to a high-quality drug product presents a complex challenge. Learn how partnering with a single contract manufacturer can alleviate potential risks.